Regulatory delays at Malaysia facility
FDA issued a CRL for insulin aspart due to pre-approval inspection deficiencies at the Malaysia facility; resolution timeline uncertain.
BIOCON / Q2-FY24 / risks
Keep the risk register visible.
Biocon · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Slower adalimumab (Hulio) uptake in US
Market adoption of adalimumab biosimilars has been slower than anticipated, impacting Hulio's revenue contribution; management expects improvement only in 2024-25.
Pricing pressure in generics API business
API business faced pricing pressure and muted offtake due to customer inventory stocking; recovery expected but uncertain.
High debt and interest costs
Net debt to EBITDA elevated; interest costs rising due to high rate environment; deferred payments in FY25 may require additional funding.